# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jack London (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET010-SYN
- Date: 2026-08-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe-Ibe, MD
- Calendar frame: modern shifted

## What we are working on

- Tired by afternoon, with swollen ankles, and frightened by the word 'kidneys' again **S**
- He knows the drinking is hurting him and wants to stop without losing his work **S**
- He wants to keep writing a thousand words every morning **S**

## Your goals

- Find out how much kidney function is lost, how long it has been so, and why. Target: 2026-08-18. Recorded outcome: Chronic kidney disease G3b A2 from hypertension with naproxen contributing; no stones, obstruction or glomerular disease suspected. **S**
- Stop drinking safely, and stay stopped. Target: 2027-02-02. Recorded outcome: Withdrawal completed without complications; one evening of drinking at four weeks; abstinent since, with PEth 8 and then 6 ng/mL. **S**
- Blood pressure below 120 systolic by standardized office measurement if tolerated, and at least below 130/80. Target: 2027-02-02. Recorded outcome: 158/98 to 122/78 at twelve weeks on losartan 100 mg. **S**
- Urine albumin down by at least 30 percent. Target: 2026-10-27. Recorded outcome: 240 to 96 mg/g on losartan and then dapagliflozin. **S**
- No anti-inflammatory pain medicines, and pain controlled. Target: 2026-10-27. Recorded outcome: No naproxen since intake; acetaminophen and topical treatment only, including for an ankle sprain. **S**
- Keep the morning writing hours. Target: 2026-10-27. Recorded outcome: Wrote every morning through the twelve weeks except the two days of the worst withdrawal. **S**

## What we agreed to do

- Kidneys and blood pressure: creatinine with eGFR (CKD-EPI 2021), urine albumin-to-creatinine ratio and urinalysis with microscopy, electrolytes and bicarbonate, uric acid, calcium, phosphate and PTH, blood count, HbA1c and a lipid panel once; the earlier insurance creatinine obtained; ultrasound of the kidneys and liver; standardized office blood pressure at every visit and home readings. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Nephrology consultation to confirm the stage and cause of the kidney disease and advise on blood pressure, an SGLT2 inhibitor, medicines for alcohol use disorder at his kidney function, and pain relief. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021) **S**
- Losartan 50 mg daily from intake, raised to the maximum tolerated dose, with potassium and creatinine two to four weeks after each start or change, accepting a rise in creatinine of up to 30 percent; less salt. Guideline: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Alcohol: AUDIT, DSM-5-TR criteria and PEth with consent; liver tests and FIB-4; a withdrawal-risk score (PAWSS) and outpatient withdrawal with a five-day chlordiazepoxide taper, daily telephone checks and thiamine; addiction-focused counseling with the clinic's addiction medicine team each week and mutual-help meetings if he wishes; PEth and liver tests at follow-up. Guideline: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025) **S**
- Medicine for alcohol use disorder: naltrexone 50 mg daily, which needs no dose change at his kidney function, with liver tests and a wallet card about opioid blockade; acamprosate not chosen because it needs a lower dose at his creatinine clearance and is avoided below 30 mL/min, and he could not reliably take it three times a day. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**
- Liver: ultrasound and vibration-controlled transient elastography for an indeterminate FIB-4; abstinence as the treatment. Guideline: Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025) **S**
- SGLT2 inhibitor (dapagliflozin 10 mg daily) once he has been abstinent for some weeks and is eating regularly, because heavy drinking and fasting raise the risk of ketoacidosis; held on days he cannot eat or drink, with potassium and creatinine two to four weeks after starting, accepting an early fall in eGFR. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Pain and medicine safety: no naproxen, ibuprofen or other oral anti-inflammatory medicines; acetaminophen up to 2,000 mg a day; no opioids or tramadol with kidney disease and in early recovery, and none at all if naltrexone is started; any new medicine checked for kidney dosing. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Safety: a structured safety assessment, firearms locked with ammunition apart, small supplies of withdrawal medicine, a written safety plan, the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Work and recovery: keep the morning writing hours from nine to eleven; replace the late-morning drink with a swim or a ride; no alcohol kept in the writing room; PHQ-9 and GAD-7 at intake and follow-up. Guideline: VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Tobacco: advice to stop, with nicotine replacement or varenicline offered when he is ready. Guideline: Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021) **S**

## Follow-up

- 2026-08-04: Establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultation **S**
- 2026-08-18: Two-week review after stopping alcohol and starting losartan, seen the same day by nephrology: kidney staging and cause, ultrasound and elastography, blood pressure target, medicine for alcohol use disorder, and pain relief **S**
- 2026-09-15: Six-week review: drinking and PEth, blood pressure, potassium and creatinine, urine albumin, liver tests, mood and safety **S**
- 2026-09-29: Periodic adult preventive visit **S**
- 2026-10-13: Ten-week review: abstinence, potassium and creatinine after the losartan increase, and the SGLT2 inhibitor **S**
- 2026-10-27: Twelve-week review: kidney function after the SGLT2 inhibitor, urine albumin, liver tests, AUDIT, mood, safety and the plan ahead **S**

This teaching document does not replace care from a qualified clinician.
